USD 169.5
(-0.56%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 6.8 Billion USD | -15.91% |
2022 | 8.09 Billion USD | 19.98% |
2021 | 6.74 Billion USD | -8.41% |
2020 | 7.36 Billion USD | 11.36% |
2019 | 6.61 Billion USD | 2.46% |
2018 | 6.45 Billion USD | 30.26% |
2017 | 4.95 Billion USD | 10.85% |
2016 | 4.46 Billion USD | -8.22% |
2015 | 4.86 Billion USD | 33.37% |
2014 | 3.65 Billion USD | -0.19% |
2013 | 3.65 Billion USD | 528.35% |
2012 | 582 Million USD | 1.22% |
2011 | 575 Million USD | -19.13% |
2010 | 711 Million USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q3 | 6.75 Billion USD | 0.16% |
2024 Q2 | 6.74 Billion USD | -0.38% |
2024 Q1 | 6.77 Billion USD | -0.49% |
2023 Q4 | 6.8 Billion USD | 0.86% |
2023 FY | 6.8 Billion USD | -15.91% |
2023 Q2 | 6.74 Billion USD | 0.04% |
2023 Q3 | 6.74 Billion USD | 0.0% |
2023 Q1 | 6.74 Billion USD | -16.66% |
2022 Q4 | 8.09 Billion USD | 19.87% |
2022 FY | 8.09 Billion USD | 19.98% |
2022 Q2 | 6.73 Billion USD | -0.03% |
2022 Q1 | 6.73 Billion USD | -0.1% |
2022 Q3 | 6.74 Billion USD | 0.22% |
2021 Q2 | 7.34 Billion USD | -0.1% |
2021 Q3 | 6.75 Billion USD | -8.05% |
2021 FY | 6.74 Billion USD | -8.41% |
2021 Q1 | 7.35 Billion USD | -0.16% |
2021 Q4 | 6.74 Billion USD | -0.13% |
2020 Q4 | 7.36 Billion USD | -6.37% |
2020 FY | 7.36 Billion USD | 11.36% |
2020 Q1 | 6.62 Billion USD | 0.17% |
2020 Q2 | 7.85 Billion USD | 18.54% |
2020 Q3 | 7.86 Billion USD | 0.17% |
2019 Q4 | 6.61 Billion USD | -0.08% |
2019 Q1 | 6.57 Billion USD | 1.95% |
2019 Q2 | 6.61 Billion USD | 0.56% |
2019 Q3 | 6.61 Billion USD | 0.02% |
2019 FY | 6.61 Billion USD | 2.46% |
2018 Q4 | 6.45 Billion USD | 0.17% |
2018 FY | 6.45 Billion USD | 30.26% |
2018 Q3 | 6.44 Billion USD | 29.99% |
2018 Q2 | 4.95 Billion USD | 0.02% |
2018 Q1 | 4.95 Billion USD | 0.02% |
2017 Q3 | 5.7 Billion USD | 24.8% |
2017 FY | 4.95 Billion USD | 10.85% |
2017 Q2 | 4.56 Billion USD | 2.26% |
2017 Q1 | 4.46 Billion USD | 0.0% |
2017 Q4 | 4.95 Billion USD | -13.14% |
2016 FY | 4.46 Billion USD | -8.22% |
2016 Q1 | 4.46 Billion USD | -8.22% |
2016 Q3 | 4.46 Billion USD | -0.04% |
2016 Q2 | 4.46 Billion USD | 0.02% |
2016 Q4 | 4.46 Billion USD | 0.02% |
2015 FY | 4.86 Billion USD | 33.37% |
2015 Q2 | 3.64 Billion USD | 0.05% |
2015 Q4 | 4.86 Billion USD | 33.96% |
2015 Q3 | 3.63 Billion USD | -0.36% |
2015 Q1 | 3.64 Billion USD | -0.14% |
2014 Q1 | 3.65 Billion USD | 0.03% |
2014 Q2 | 3.65 Billion USD | -0.11% |
2014 Q3 | 3.65 Billion USD | -0.05% |
2014 Q4 | 3.65 Billion USD | -0.05% |
2014 FY | 3.65 Billion USD | -0.19% |
2013 FY | 3.65 Billion USD | 528.35% |
2013 Q1 | 3.64 Billion USD | 526.46% |
2013 Q2 | 3.65 Billion USD | 0.16% |
2013 Q3 | 3.65 Billion USD | 0.0% |
2013 Q4 | 3.65 Billion USD | 0.14% |
2012 Q4 | 582 Million USD | 0.34% |
2012 Q2 | 573 Million USD | -1.04% |
2012 Q3 | 580 Million USD | 1.22% |
2012 FY | 582 Million USD | 1.22% |
2012 Q1 | 579 Million USD | 0.7% |
2011 FY | 575 Million USD | -19.13% |
2011 Q4 | 575 Million USD | 0.0% |
2010 FY | 711 Million USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Editas Medicine, Inc. | 36.53 Million USD | -18519.991% |
Dynavax Technologies Corporation | 256.91 Million USD | -2547.968% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -16282.113% |
Perrigo Company plc | 4.07 Billion USD | -67.01% |
Illumina, Inc. | 2.26 Billion USD | -200.752% |
Thermo Fisher Scientific Inc. | 34.91 Billion USD | 80.517% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -680200.0% |
Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 28.794% |
IQVIA Holdings Inc. | 14.23 Billion USD | 52.196% |
Heron Therapeutics, Inc. | 173.75 Million USD | -3815.328% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -151.693% |
Unity Biotechnology, Inc. | 26.99 Million USD | -25105.632% |
Waters Corporation | 2.35 Billion USD | -188.812% |
Biogen Inc. | 7.33 Billion USD | 7.293% |
Sangamo Therapeutics, Inc. | 38.1 Million USD | -17753.769% |
Evolus, Inc. | 126.54 Million USD | -5275.911% |
Adicet Bio, Inc. | 17.7 Million USD | -38328.515% |
Cara Therapeutics, Inc. | 43.16 Million USD | -15659.724% |
bluebird bio, Inc. | 330.32 Million USD | -1959.481% |
Esperion Therapeutics, Inc. | 540.94 Million USD | -1157.609% |
FibroGen, Inc. | 170.45 Million USD | -3891.083% |
Agilent Technologies, Inc. | 2.73 Billion USD | -148.739% |
Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -32474.815% |
Homology Medicines, Inc. | 44.05 Million USD | -15342.412% |
Geron Corporation | 85.89 Million USD | -7819.766% |
Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | -183.693% |
Amicus Therapeutics, Inc. | 445.05 Million USD | -1428.561% |
Myriad Genetics, Inc. | 145 Million USD | -4591.724% |
Viking Therapeutics, Inc. | 1.26 Million USD | -539820.635% |
Intellia Therapeutics, Inc. | 115.34 Million USD | -5797.907% |
Abeona Therapeutics Inc. | 4.4 Million USD | -154443.389% |
Mettler-Toledo International Inc. | 2.16 Billion USD | -213.825% |
BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -499.978% |
Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -741.539% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | -18629.18% |
Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | -368.03% |
Atara Biotherapeutics, Inc. | 57.87 Million USD | -11655.253% |
Verastem, Inc. | 41.55 Million USD | -16270.287% |
Nektar Therapeutics | 230.4 Million USD | -2852.678% |
Axsome Therapeutics, Inc. | 186.37 Million USD | -3550.226% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -221207.742% |
Sarepta Therapeutics, Inc. | 1.39 Billion USD | -387.039% |
OPKO Health, Inc. | 326.56 Million USD | -1983.206% |
Exelixis, Inc. | 189.94 Million USD | -3481.582% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | -1488.002% |
Corcept Therapeutics Incorporated | 151 Thousand USD | -4505198.013% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 138.4 Million USD | -4815.143% |
Imunon, Inc. | 1.13 Million USD | -597024.708% |
Blueprint Medicines Corporation | 774.12 Million USD | -778.802% |
Insmed Incorporated | 1.2 Billion USD | -465.036% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | -353.761% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -11837.601% |
TG Therapeutics, Inc. | 110.79 Million USD | -6040.169% |
Incyte Corporation | 38.28 Million USD | -17668.433% |
Emergent BioSolutions Inc. | 877.5 Million USD | -675.271% |